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Prevalence of Autism Spectrum Disorder Phenomenology in Genetic Disorders:  
A Systematic Review and Meta-Analysis 
 
Summary 
Background Autism spectrum disorder (ASD) phenomenology is reported to be more 
common in individuals with some genetic syndromes than in the general population; 
however, no meta-analysis has provided prevalence data within and between syndromes. In 
this systematic review and meta-analysis, we aimed to synthesise data from a wide range of 
papers to provide accurate estimates about ASD phenomenology in genetic and metabolic 
syndromes. 
 
Methods We identified syndromes reported as most likely to be associated with ASD. We 
searched Ovid PsycINFO, Ovid MEDLINE, Ovid Embase and PubMed Central for English-
language papers published from database creation up to early 2014 with use of syndrome-
specific keywords and a set of ASD keywords. We screened and extracted papers that had 
ASD prevalence data for ten or more people within a genetic syndrome. With use of a 
prespecified set of reliable criteria, we applied quality weighting to papers and estimated a 
quality-effects prevalence of ASD phenomenology for each syndrome. We then calculated 
relative risks to compare ASD between all syndromes and also calculated odds ratios to 
compare prevalence with the general population taking the current estimate of one in 68 
people. 
 
Results We identified 168 papers reporting the prevalence of ASD phenomenology and 
found widely varying methods and quality of data. Quality-weighted effect prevalence 
estimates of ASD phenomenology were established for Rett’s syndrome (female individuals 
only 61%), Cohen’s syndrome (54%), Cornelia de Lange syndrome (43%), tuberous sclerosis 
complex (36%), Angelman’s syndrome (34%), CHARGE syndrome (30%), fragile X 
syndrome (male individuals only 30%; mixed sex 22%) neurofibromatosis type 1 (18%), 
Down’s syndrome (16%), Noonan’s syndrome (15%), Williams’ syndrome (12%) and 
22q11.2 deletion syndrome (11%). Relative risks and the odds ratio compared with the 
general population were highest for Rett’s syndrome and Cohen’s syndrome. In all 
syndromes, odds ratios showed ASD phenomenology to be significantly more likely than in 
the general population.  
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Interpretation ASD phenomenology varied between syndromes, but was consistently more 
likely than in the general population. Further research is needed in these populations, 
including how ASD in genetic and metabolic syndromes differs from idiopathic autism and 
what that can tell us about the mechanism underlying ASD. 
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Introduction 
Autism spectrum disorder (ASD) is a broad term for a group of behaviourally defined 
neurodevelopmental disorders that historically includes autistic disorder, childhood autism, 
pervasive developmental disorder – not otherwise specified (PDD-NOS), and Asperger’s 
syndrome.
1,2
 ASD is defined by the presence of abnormalities or impairments in social 
interaction and communication, with accompanying restricted or repetitive behaviours, 
activities, or interests. Estimates for the prevalence of ASD in the general population range 
from one in 100 people
3,4
 to one in 68.
5
 However, despite the high prevalence and robust 
research documenting heritability,
6
 genetic aetiological cause has yet to be identified. This 
absence might be partly because of the methodological challenges caused by the behavioural 
heterogeneity within the spectrum.
7
 
 
ASD phenomenology seems more prevalent in individuals with specific genetic and 
metabolic syndromes than in those without these syndromes.
8,9
 Study of the prevalence and 
phenomenology of ASD within and across these syndromes could disentangle the genetic and 
biological pathways that underlie idiopathic ASD.
7,10,11
 Recent findings show that particular 
rare de-novo or transmitted copy number variations substantially increase the risk of ASD.
12
 
Through studying the downstream disruption caused by these variations, reserachers are 
identifying candidate ASD-associated genes. From these biological markers, it might be 
possible to identify specific cognitive deficits that underpin characteristic idiopathic ASD 
behaviours.  
 
Evidence is emerging that individuals with certain genetic and metabolic syndromes might 
have an atypical profile of ASD phenomenology, which would support a distinction between 
syndromic variants of ASD and idiopathic ASD.
13-15
 A pragmatic strategy to evaluate the 
presence of syndromic variants of ASD would be to conduct detailed analysis of ASD 
phenomenology in syndromes in which prevalence estimates for ASD are consistently high. 
However, despite many systematic reviews
16-19
 no meta-analytic studies have documented the 
consistency of prevalence data within syndromes, calculated variation of prevalence 
estimates between syndromes, or compared prevalence estimates to those for the general 
population.  
 
Several methodological challenges complicate synthesis of prevalence data for ASD 
phenomenology across syndromes. First, the diagnosis of ASD in clinical practice requires 
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rigorous multicomponent assessment, with information collected from many sources and 
across contexts.
19
 This depth and breadth of diagnostic assessment is rarely replicated in 
research, and any prevalence statistics are thus more accurately described as estimates of the 
presence of ASD phenomenology, rather than estimates of the presence of diagnostically 
defined ASD. Additionally, many studies rely solely on screening measures which take less 
time and resources. However, screening measures often have low specificity and 
sensitivity
14,20
 and thus the prevalence data have wide confidence intervals. Diagnostic 
measures have greater sensitivity and specificity, however, prevalence data may be biased 
because accuracy is lowest for marginal or unusual cases, such as those with intellectual 
disability.
20
  
 
The association between ASD phenomenology and greater severity of intellectual disability
21
 
is hypothesised to contribute to the behavioural phenotypes associated with genetic 
syndromes, such that associated degree of disability, rather than the presence of the syndrome 
itself, more fully accounts for the presence of ASD in these groups.
22
 Although this pattern of 
association is often evident in individual syndrome groups, sometimes the association 
between ASD and intellectual disability is less robust. For example, in Cri du Chat syndrome, 
intellectual disability is usually severe and prevalence of ASD is relatively low compared 
with syndromes with similar levels of intellectual disability, even after controlling for 
intellectual functioning.
23
 Conversely, individuals with fragile X syndrome seem at increased 
risk of ASD phenomenology despite a wide range of intellectual functioning in the group – 
although within this group, ASD phenomenology is negatively associated with IQ.
14
 
Individuals with Cornelia de Lange syndrome show higher amounts of ASD phenomenology 
than do individuals with intellectual disability of heterogeneous aetiology with comparable 
adaptive functioning.
24
 Available models of this association are based on individual empirical 
studies that are limited by small samples and cohort effects. The delineation of robust rates of 
ASD phenomenology for each syndrome through meta-analytic methods would advance 
attempts to evaluate comprehensively the association between ASD phenomenology and 
intellectual disability in syndromes.  
 
In this systematic review and meta-analysis, we aimed to describe and evaluate the scientific 
literature for ASD phenomenology in genetic and metabolic syndromes and to generate 
pooled estimates for prevalence of ASD phenomenology within each syndrome, weighted by 
the quantity and quality of the available evidence; to make preliminary comparisons of the 
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pooled prevalence estimates across syndromes; and to compare pooled prevalence estimates 
in the syndromes with estimates of ASD in the general population. 
 
Methods 
Search strategy and selection criteria 
With use of a 2009 review, we generated a list of 21 syndromes most likely to be associated 
with ASD.
15
 The review highlighted genetic syndromes in which at least one empirical study 
had been done and previous systematic reviews had described the syndrome to be associated 
with ASD. We did literature searches in Ovid PsycINFO, Ovid MEDLINE, Ovid Embase, 
and PubMed Central for English-language papers published from database creation up to 
early 2014 (appendix). Searches were done by combining autism search terms with all 
variations of the syndrome search terms (listed in appendix). The autism search terms 
included “autis*”, “autism*”, “autistic*”, “ASD”, “autism spectrum disorder*”, “PDD-
NOS”, “PDDNOS”, “unspecified PDD”, “pervasive developmental disorder*”, “pervasive 
developmental disorder not otherwise specified”, “Asperger*”, and “Asperger* syndrome”. 
Additionally, we hand-searched the reference list of Moss and Howlin
15
 to identify papers. 
 
We then assessed papers from the search in three stages. LG screened papers by review of 
abstracts and titles. Papers were included if they were empirical papers; published or 
available in English; included a participant sample of ten people or more; and indicated in the 
abstract that the paper reported on the prevalence of ASD within a genetic syndrome group. 
For any papers where suitability was unclear CR reviewed the paper for consensus. 
 
CR read the full texts of screened papers to assess eligibility of the data. The same inclusion 
and exclusion criteria were used at screening and eligibility. However, the following 
additional inclusion criteria were specified at the eligibility stage: the paper reports the 
number of participants who met a clinical cut off for ASD, participants were recruited 
without any specific bias, and the study reports on a unique sample (or a potentially 
overlapping sample, but the proportion of overlap cannot be readily determined). When 
samples were identical, the paper with the highest quality rating was included in the analysis 
to ensure the most robust pooled prevalence estimates.  
 
The quality of the remaining papers was then assessed according to the quality criteria listed 
later. Papers were included if they had a minimum quality weighting of 0·33 by a 
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combination of scores from at least two criteria. If at any stage, the number of papers 
remaining in a syndrome group was lower than two, the group was removed from the analysis 
(appendix).  
 
Quality review and data extraction 
We generated a numerical quality weighting for each study through a quality review and used 
these data to weight the influence of individual studies in the quality-effects pooled 
prevalence estimate for each syndrome. Because this was the first statistical meta-analysis of 
ASD phenomenology in syndromes and research was scarce for some syndromes, a 
pragmatic decision was taken to delineate broad quality criteria that allowed for the 
maximum inclusion of studies, whilst weighting prevalence estimates from the most robust 
studies more heavily.  
 
The quality criteria were generated through review of standardised quality criteria for 
intervention studies
25
 and prevalence studies.
26
 To control for key threats to validity, we 
devised idiosyncratic quality criteria for the selection of the samples with syndromes, the 
confirmation of syndrome, and the assessment of ASD. For each of these criteria, we did 
literature reviews and consulted active research experts in autism and rare syndromes for 
advice about areas of methodological concern. 
 
To provide a simple visual matrix, when quality ratings are provided for each syndrome, the 
criteria were coded as red for a score of zero, yellow for a score of one, amber for a score of 
two and green for a score of three (appendix). The quality weighting was calculated by 
dividing the total quality score by the maximum possible total of nine. All studies which met 
the inclusion criteria were read by CR and rated for quality within these criteria.  
 
From each paper selected, we extracted the number and percentage of the sample individuals 
who met clinical cutoff for ASD phenomenology. The clinical cutoff varied for each measure 
of ASD assessment used. When an assessment provided multiple cutoffs (eg, PDD-NOS vs 
autistic disorder), the most conservative cutoff for the most severe level of ASD 
phenomenology was entered into the meta-analysis.  
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Statistical analysis 
We used MetaXL version 2.0 (EpiGear, QLD, Australia) to generate pooled prevalence 
estimates. Because studies in this review are all of variable methodological quality, we used a 
random-effects model to calculate prevalence.  Additionally, we constructed a quality-effects 
model based on methodological quality ratings.
 
Here, the weightings were derived directly 
from the quality index score (as reported above) as well as the study’s sample size. To avoid 
confidence intervals for the pooled prevalence estimates falling outside of the 0.1 boundaries, 
we applied the double-arcsine back transformation to both the random-effects and quality-
effects models. 
 
To make comparisons across syndromes, we plotted the random-effects and quality-effects 
pooled prevalence estimates for each group against one another. Due to the large number of 
between-group tests, more conservative (99%) confidence intervals were selected. We 
calculated relative risk statistics using 99% CIs to assess the relative likelihood of ASD 
phenomenology in each syndrome using the quality-effects prevalence.  
 
Finally, to compare ASD phenomenology in each syndrome with an estimated prevalence in 
the general population, we generated odds ratios (OR) with 95% CI, comparing the quality-
effects pooled prevalence for each syndrome with the most recent total population prevalence 
estimate for ASD diagnosis (one in 68).
5
 Although this total population prevalence estimate 
of ASD diagnosis is significantly higher than previous estimates, we felt to be the most 
appropriate comparison for meta-analysis, because any identified increased likelihood of 
ASD phenomenology in the syndrome groups could not be attributed to overly conservative 
estimates for the general population prevalence. 
 
Role of the funding source  
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
 
Results  
We identified 32230 papers and selected 168 papers across 16 syndromes, as suitable for 
qualitative review (figure 1, table 1).  
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+++++++++++++++++Insert Figure 1 about here++++++++++++++ 
 
Across syndromes, only nine (5·4%) papers met criteria for the highest quality rating for 
sample identification, whereas 89 (53·0%) obtained the highest quality rating for syndrome 
confirmation and, 43 (25·6%) for ASD assessment. Only one (0·6%) paper met the highest 
quality rating for all three quality criteria. Nine (5·4%) papers were excluded from the pooled 
prevalence estimates because they did not meet the required quality inclusion criteria. To 
establish the reliability of our quality criteria, 52 (32%) of all studies were independently 
rated by a second researcher. The correlation coefficient for total quality weighting was good 
(r(52)=0.78, p<0.001). 
 
In total, 54 (32·1%) papers reported on the profile of ASD phenomenology within a 
syndrome, in addition to reporting the prevalence. Most papers (n=91, 54·1%) reported the 
proportion of the sample that had an intellectual disability. Further data for participant 
characteristics, the ASD measures used, and forest plots of the random-effects and quality-
effects prevalence estimates are in the appendix.  
 
+++++++++++++++++Insert Table 1 about here++++++++++++++ 
 
 ASD phenomenology ranged in prevalence across the 12 syndromes that met inclusion 
criteria for comparison, from a quality-weighted effect prevalence of 61% (95% CI 46·0–
74·0) in individuals with Rett’s syndrome to 11% (5·0–19·0) in those with 22q11.2 deletion 
syndrome (table 1; figure 2). Prevalence estimates were also generated for Möbius’ 
syndrome, phenylketonuria, and Joubert’s syndrome (table 1), but these data were not 
deemed to be robust due to the wide confidence intervals including zero. Data for fragile X 
syndrome in male individuals were excluded to prevent overlap. 
 
++++++++++++ Insert Figure 2 about here++++++++++++++ 
 
Table 2 presents the relative risk for ASD prevalence between the 12 syndromes that were 
robust enough for comparison. ASD phenomenology was significantly more likely in Rett’s 
and Cohen’s syndromes than in all other syndromes (table 2). Relative risks were moderate 
for tuberous sclerosis complex, Cornelia de Lange syndome, CHARGE syndrome and 
Angelman’s syndrome compared with others. ASD phenomenology was significantly less 
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likely in Noonan’s, 22q11.2 deletion, Williams’ and Down’s syndromes than in most other 
syndromes.  
 
+++++++++++++++++Insert Table 2 about here++++++++++++++ 
 
For the final aim of the meta-analysis, we generated odds ratios to compare each syndrome 
with the most recent estimates for ASD diagnoses in the general population (figure 3). ASD 
phenomenology was significantly more likely in all syndromes compared than in the general 
population. Odds ratios ranged from 8·3 (95% CI 1·04–65·73) for 22q11.2 deletion syndrome 
to 104·8 (95% CI 13.97–786.08) for Rett’s syndrome. ASD phenomenology was significantly 
more likely for boys and men with fragile X syndrome, compared with the general population 
(OR 28·7, 95% CI 3·8 – 216·5). 
 
+++++++++++++++++Insert Figure 3 about here++++++++++++++ 
 
Discussion 
In this meta-analysis, we present pooled data and cross-syndrome comparisons for the 
prevalence of ASD phenomenology in rare genetic and metabolic syndromes. To our 
knowledge this was the first meta-analysis of the prevalence of ASD phenomenology across 
many genetic syndromes and thus extended findings from previous systematic reviews.
14–17
 
Our wide search criteria and screening of both abstracts and titles during the initial search 
stages allowed the identification and inclusion of a greater number of studies than previous 
systematic reviews. The creation of a unique quality rating scheme to evaluate and weight the 
prevalence data further strengthened the findings.  
 
ASD phenomenology was highly prevalent in Cohen’s and Rett’s syndromes. Despite cross-
syndrome differences, the odds of the presence of ASD phenomenology were increased by 
between eight and 105 times in all syndromes compared to the odds of ASD diagnosis in the 
general population.  The pooled prevalence estimates ranged from 61% in individuals with 
Rett’s syndrome to 11% in individuals with 22q11.2 deletion syndrome. Overall, the 
generated prevalence figures were similar to previous prevalence range estimates cited in 
systematic reviews.
14–17
 However, there were several differences. First, the prevalence figure 
of 22% we show for fragile X syndrome was at the very low end of the range indicated by 
Moss and Howlin (21-50%)
15
 and Zafeiriou and colleagues (22-33%).
16
 The more 
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conservative prevalence estimate from this meta-analysis was probably due to the inclusion 
of data from both male and female individuals with fragile X syndrome. Our prevalence 
estimate for only boys and men of 30% was consistent with that from previous reviews.
15,16
 
However, to maintain parity with other syndromes, we used the generated prevalence 
estimate including data from mixed sex samples to do cross-syndrome comparisons. 
Secondly, the generated prevalence estimates for Cornelia de Lange, Angelman’s, Down’s 
and 22q11.2 deletion syndromes were slightly more conservative than some of the ranges 
reported in previous systematic reviews (Cornelia de Lange syndrome 50-67%,
14
 46-67%;
16
 
Angelman’s syndrome 50-81%,14 50-61%;16 22q11.2 deletion syndrome 20-31%,17 14-
50%
16
). In all cases, the prevalence estimates in the systematic reviews were based upon far 
fewer studies than the prevalence estimate for this meta-analysis.
15,16
 Additionally, this 
review aimed to improve the quality of prevalence estimates for each of the syndromes by 
including quality review and weighting the most robust estimates more heavily. Thus, while 
the reported prevalence data might be more conservative than previous reports in some cases, 
it is probably also more robust.  
 
Our meta-analysis allowed comparisons of ASD prevalence between syndromes and with the 
general population. Findings show syndromes can be clustered into group of prevalence; 
those in which ASD phenomenology was comparitively highly likely (Rett’s and Cohen’s 
syndromes), moderately likely (tuberous sclerosis complex, Cornelia de Lange, CHARGE, 
and Angelman’s syndrome), less likely (fragile X syndrome and neurofibramatosis type 1), 
and least likely (22q11.2 deletion, Noonan’s, Williams’, and Down’s syndromes). The results 
show that even within a group of syndromes known to have increased ASD phenomenology, 
much variation exists. These data can be used to guide research into underlying pathways of 
idiopathic ASD. Focus on mechanisms in syndromes in which ASD is highly likely might 
allow exploration of the cognitive and genetic explanations for idiopathic ASD. Some 
researchers have begun to reject unified explanations of ASD phenomenology and instead 
suggest fractionation of the social communicative and repetitive impairments present in 
idiopathic ASD.
27
 However, research in idiopathic ASD is made difficult by the constraint of 
behavioural diagnosis – ie, individuals are included in studies because of an ASD diagnosis 
that necessitates impairments in social communicative and repetitive domains, and then these 
individuals are assessed to investigate the unitary coherence of these impairments. 
Investigation of the overlap and differences of social communication and repetitive 
impairments in these high-risk syndromes would progress unitary or fractionated models of 
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ASD, while also removing the inclusion bias in studies of individuals with idiopathic ASD. 
Examples of this include delineation of the profile of ASD in Cornelia de Lange syndrome,
28
 
fragile X syndrome
14,28
 and Down’s syndrome.29    
 
The results of this analysis have important implications for clinical and educational services 
for individuals with genetic syndromes, in all of which our results show a greater risk of 
ASD-type behaviours than in the general population. Irrespective of empirical or conceptual 
questions about whether these behaviours are commensurate with idiopathic ASD, the 
presence of ASD-like difficulties in communication, social interaction, and restrictive and 
repetitive behaviours in those with these syndromes should lead to the same tailored support 
for affected individuals that has been proposed for those with idiopathic ASD. Assessments 
should also include an exploration of the impact of any identified ASD impairments on the 
individual’s quality of life, and that of their families and carers. In some cases, specific 
educational placements might be of benefit. Also, ASD-specific clinical interventions to 
support communication and social skills development could be useful. Most importantly, 
these results show the importance of reducing diagnostic overshadowing, in which all social 
and communicative difficulties in a syndrome are attributed solely to the genetic syndrome, 
and highlights the need to assess and identify concurrent ASD impairments.
15
  
 
The meta-analysis has also provided opportunity to evaluate and compare research 
methodologies used to assess the prevalence of ASD phenomenology within and between 
syndromes. A key issue that arose was a propensity for research groups to publish data that 
appeared to have been collected in a similar but not identical sample in multiple papers. 
Although legitimate reasons might exist for doing so, specifically for publishing data about 
different aspects of the same syndrome, it is imperative for authors to fully describe their 
sample, and whether the whole sample or a proportion of the sample have been reported 
previously. This is a key area for improvement in future research.  
 
We identified much variability in the reporting of the professional who interpreted the ASD 
assessments. When ASD assessments require clinical interpretation (eg, Childhood Autism 
Rating Scale [CARS]) or substantial pre-assessment training (eg, Autism Diagnostic 
Interview-Revised [ADI-R] or Autism Diagnostic Observation Schedule [ADOS]), studies 
should report the role, qualification, or level of training of the examiner clearly. For the 
purposes of this review, we needed to include as many studies as possible. However, future 
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reviews should seek to use more stringent inclusion criteria, requiring adequate description of 
the delivery and interpretation of ASD assessment tools. Use of these inclusion criteria would 
have reduced the number of papers in the present meta-analysis.  
 
The quality of description of intellectual disability within our included studies was also 
variable. Only half of the studies (54%) reported the proportion of their participants with an 
intellectual disability, and there was great variability in the assessment used (ranging from an 
individual question delivered to parents or carers to psychometrically robust cognitive 
assessment). Between-groups visual inspection showed that groups with higher levels of 
intellectual functioning (Williams’ syndrome and neurofibromatosis type 1) had substantial 
lower risk of ASD phenomenology compared with groups with expected low intellectual 
functioning. Conversely, Rett’s syndrome had the highest risk of ASD; individuals with 
Rett’s syndrome typically have an intellectual disability in the severe to profound range. 
These broad associations are in line with models that suggest that impaired intellectual 
functioning in syndromes accounts for the presence of ASD phenomenology, whether that be 
through a reduction in the ability to compensate for inherited autistic traits or through other 
mechanisms.
21
 However, in several groups in whom intellectual functioning is reported to be 
variable, heightened risk of ASD phenomenology was also evidenced (Cornelia de Lange 
syndrome, Cohen’s syndrome). Thus, the role of intellectual functioning in the presence and 
prevalence of ASD in syndromes should be further elucidated. Investigators should 
appropriately assess intellectual disability using robust direct cognitive measures, and analyse 
how far intellectual disability can account for ASD phenomenology. Also needed is statistical 
meta-analytic review for the contribution of intellectual disability to the prevalence of ASD 
phenomenology in syndromes. The combination of robust empirical studies and 
comprehensive meta-analytic review would substantially progress understanding for the 
relative contributions of mechanisms underlying genetic syndromes, intellectual functioning 
and ASD phenomenology. 
 
The results from this meta-analysis can serve to highlight areas for future research. First, six 
syndromes (Goldenhar’s, Sotos’, Ehlers-Danlos, Lujan-Fryns, Leber’s congenital amaurosis, 
and hypomelanosis of Ito) were excluded from the meta-analysis on the basis of a paucity of 
research delineating the prevalence of ASD phenomenology in these groups (appendix). 
Additionally, generated pooled prevalence estimates for phenylketonuria, Joubert’s, and 
Möbius’ were not sufficiently robust to allow for further interpretation or cross-syndrome 
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comparison. Thus, given the putative associations between each of these syndromes and ASD 
phenomenology, robust research for each of these groups is needed to detail the prevalence 
and profile of ASD phenomenology. Second, given the wide variety of ASD assessments and 
reported differences in the sensitivity and specificity of these instruments,
20
 researchers 
should evaluate the reliability and validity of ASD assessments in marginal populations such 
as individuals with syndromes and intellectual disability, and to examine the differing 
prevalence data that these assessments generate. Johansson and colleagues
30
 present a useful 
way to do this type of research and contrast the use of the ADI-R, CARS and Autism 
Behavior Checklist to identify ASD phenomenology in Möbius’, CHARGE, and Goldenhar’s 
syndromes. This method could be usefully applied across other groups to reach a consensus 
on the most appropriate ASD assessments for use in syndromes, in both research and clinical 
practice.  
 
A final and key area for future research is to detail more robustly the profile of ASD 
phenomenology in each syndrome. Emerging evidence suggests that the profile of ASD 
impairments within syndromes might be qualitatively different in phenomenology to that of 
idiopathic ASD.  This might be evidenced through uneven profiles of impairments, in which 
individuals with certain syndromes evidence difficulties in some areas of ASD 
phenomenology but not others.
14,15
 Thus the generated prevalence data in this meta-analysis 
might not reflect the prevalence of diagnosable ASD in which impairment is necessary in 
both social communicative domains and repetitive and restricted behaviours.  
 
This meta-analysis has highlighted those syndromes in which the data for the profile of ASD 
are accumulating (eg, fragile X, Cornelia de Lange, Down’s and Angelman’s syndromes) and 
by exclusion, those syndromes in which this is still under-researched. Work should seek to 
synthesise findings across studies on the profile of ASD in these well researched syndromes. 
Additionally, further empirical research is needed in the remaining syndromes to delineate 
the profile of ASD in these groups. A review of syndromes that have been identified to be 
associated with ASD phenomenology more recently should also be done. Genetic or 
metabolic confirmation of syndromes, where appropriate, would allow more precise links 
between causal mechanism and ASD profile. Gold-standard assessments of the profile of 
ASD phenomenology should include comparison with other syndrome groups to assess 
degree of intellectual disability and comparisons to idiopathic ASD to evaluate the 
similarities and differences in the profile of behaviour. The generation of these data could 
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improve delineation of the psychological constructs associated with ASD in each of these 
syndromes, specifically the cognitive and social profiles and their developmental trajectories, 
although these will be mediated by the level of intellectual disability associated with each 
syndrome. As detailed assessment of the behavioural phenomenon in each syndrome 
develops, differences in ASD phenomenology might emerge, which might align with or 
disagree with the postulated cognitive underpinnings of idiopathic ASD (eg, theory of mind 
deficits, weak central coherence, deficits in executive functioning). 
 
In summary, this meta-analysis has generated robust estimates for the prevalence of ASD 
phenomenology for 12 genetic and metabolic syndromes. Despite between-syndrome 
variations in these prevalence data, ASD phenomenology was significantly more likely in all 
of the syndromes than in the general population.  
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Figure 1: Study selection  
 
 
 
*For more detailed explanation about exclusions see appendix.
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Table 1. Study characteristics and weighting scores, and pooled prevalence for ASD for all 16 genetic and metabolic syndromes 
 
 
Studies 
 
Patients 
(n) 
Mean 
quality 
weighting 
Individual scores Quality weighting score Prevalence of ASD 
Obtained 
score of 3 
for sample 
 Obtained 
score of 3 
for 
syndrome 
Obtained 
score of 3 
for ASD  
 Poor Adequate Good 
Random- effects 
pooled prevalence 
Quality- effects 
pooled prevalence 
Fragile X 
syndrome 
56 4089 0·63 (0·16) 1 (1·8%) 50 (89·3%) 15 (26·8%) 
10 
(17·9%) 
31 (55·4%) 
15 
(26·8%) 
26·0% (20·0–31·0) 22·0% (15·0–30·0) 
Fragile X 
syndrome (boys 
and men only)* 
28 1370 0·61 (0·17) 0 23 (82·1%) 7 (25·0%) 
6 
(21·4%) 
16 (57·1%) 
6 
(21·4%) 
28·0% (21·0–36·0) 30·0% (22·0–38·0) 
Tuberous sclerosis 
complex 
25 1434 0·55 (0·15) 2 (8·0%) 5 (20·0%) 8 (32·0%) 
11 
(44·0% 
10 (40·0%) 
4 
(16·0%) 
37·0% (33·0–40·0) 36·0% (33·0–40·0) 
22q11.2 deletion 
syndrome 
14 830 0·69 (0·15) 0 14 (100%) 6 (42·9%) 1 (7·1%) 6 (42·9%) 
7 
(50·0%) 
12·0% (6·0–19·0) 11·0% (5·0–19·0) 
Cornelia de Lange 
syndrome 
12 598 0·55 (0·13) 0 1 (8·3%) 2 (16·7%) 
6 
(50·0%) 
4 (33·3%) 
2 
(16·7%) 
4 
43·0% (33·0–54·0) 43·0% (32·0–53·0) 
Down’s syndrome 10 1084 0·54 (0·20) 3 (30·0%) 4 (40·0%) 1 (10·0%) 
6 
(60·0%) 
2 (20·0%) 
2 
(20·0%) 
16·0% (9·0–23·0) 16·0% (8·0–24·0) 
Angelman’s 
syndrome 
7 245 0·68 (0·18) 0 5 (71·4%) 3 (42·9%) 
2 
(28·6%) 
1 (14·3%) 
4 
(57·1%) 
35·0% (24·0–38·0) 34·0% (24·0–37·0) 
Neurofibromatosis 
type 1 
6 412 0·57 (0·18) 2 (33·3%) 0 1 (16·7%) 
3 
(50·0%) 
2 (33·3%) 
1 
(16·7%) 
16·0% (8·0–26·0) 18·0% (9·0–29·0) 
Williams’ 
syndrome 
5 119 0·65 (0·20 0 5 (100·0%) 1 (20·0%) 
1 
(20·0%) 
1 (20·0%) 
3 
(60·0%) 
14·0% (8·0–21·0) 12·0% (6·0–20·0) 
Rett’s syndrome 
(girls and women 
only)† 
5 194 0·51 (0·10) 0 2 (40·0%) 0 
3 
(60·0%) 
1 (20·0%) 
1 
(20·0%) 
61·0% (47·0–75·0) 61·0% (46·0–74·0) 
CHARGE 
syndrome 
4 232 0·64 (0·21) 1 (25·0%) 0 2 (50·0%) 
1 
(25·0%) 
1 (25·0%) 
2 
(50·0%) 
29·0% (14·0–48·0) 30·0% (13·0–48·0) 
Möbius’ 
syndrome* 
4 94 0·59 (0·11) 0 0 2 (50·0%) 
1 
(25·0%) 
3 (75·0%) 0 9·0% (0·0–25·0) 7·0% (0·0–22·0) 
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Studies 
 
Patients 
(n) 
Mean 
quality 
weighting 
Individual scores Quality weighting score Prevalence of ASD 
Obtained 
score of 3 
for sample 
 Obtained 
score of 3 
for 
syndrome 
Obtained 
score of 3 
for ASD  
 Poor Adequate Good 
Random- effects 
pooled prevalence 
Quality- effects 
pooled prevalence 
Phenylketonuria 
syndrome* 
3 267 0·59 (0·17) 0 2 (66·7%) 1 (33·3%) 
1 
(33·3%) 
1 (33·3%) 
1 
(33·3%) 
10·0% (1·0–27·0) 9·0% (0·0–23·0) 
Cohen’s syndrome 2 96 0·67 (0) 0 0 2 (100·0%) 0 2 (100·0%) 0 54·0% (44·0–64·0) 54·0% (44·0–64·0) 
Noonan’s 
syndrome 
2 86 0·62 (0·08) 0 1 (50·0%) 0 0 2 (100·0%) 0 16·0% (7·0–27·0) 15·0% (7·0–26·0) 
Joubert’s 
syndrome* 
2 54 0·56 (0·16) 0 0 0 
1 
(50·0%) 
1 (50·0%) 0 9·0% (0·0–50·0) 9·0% (0·0–49·0) 
Hypomelanosis of 
Ito syndrome* 
1 25 0·33 0 0 0 1 (100%) 0 0 ·· ·· 
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Figure 2: Pooled prevalence estimates of ASD phenomenology 
  
ASD=autism spectrum disorder. n=number of papers used. QW=mean quality weighting for syndrome. 
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Table 2. Relative risks (99% CI) for the prevalence of ASD phenomenology in each included syndrome compared with other syndromes  
 
Fragile X 
syndrome  
 
Tuberous 
sclerosis 
complex  
22q11.2  
 
Cornelia 
de Lange 
syndrome  
Down’s 
syndrome 
Angelman’
s 
syndrome 
Neurofibro
matosis 
type 1  
Williams’ 
syndrome 
Rett’s 
syndrome 
CHARGE 
Cohen’s 
syndrome 
Noonan’s 
syndrome 
Fragile X 
syndrome 
(moderate to 
severe) 
- 
1·64 
(0·90-2·97) 
0·50 
(0·21-1·21) 
1·95 
(1·11-3·45) 
0·73 
(0·34-1·56) 
1·55 
(0·84-2·83) 
0·82 
(0·39-1·71) 0·55 
(0·23-1·28) 
2·77 
(1·64-4·70) 
1·36 
(0·73-2·55) 
2·45 
(1·43-4·22) 
0·68 
(0·31-1·49) 
Tuberous sclerosis 
complex (normal 
to profound) 
0·61 
(0·34-1·11) 
- 
0·31 
(0·14-0·69) 
1·19 
(0·76-1·88) 
0·44 
(0·22-0·88) 
0·94 
(0·57-1·55) 
0·50 
(0·26-0·96) 
0·33 
(0·15-0·73) 
1·69 
(1·13-2·53) 
0·83 
(0·49-1·41) 
1·50 
(0·99-2·28) 
0·42 
(0·21-0·84) 
22q11.2 deletion 
(normal to severe) 
2·00 
(0·83-4·82) 
3·27 
(1·46-7·36) 
- 
3·91 
(1·77-8·63) 
1·45 
(0·57-3·73) 
3·09 
(1·37-7·00) 
1·64 
(0·65-4·10) 
1·09 
(0·40-3·00) 
5·55 
(2·59-11·89) 
2·73 
(1·19-6·27) 
4·91 
(2·27-10·62) 
1·36 
(0·52-3·55) 
Cornelia de Lange 
syndrome (mild to 
profound) 
0·51 
(0·29-0·90) 
0·84 
(0·53-1·32) 
0·26 
(0·12-0·56) 
- 
0·37 
(0.19-0.72) 
0·79 
(0·50-1·26) 
0·42 
(0·22-0·78) 
0·28 
(0·13-0·60) 
142 
(0·99-2·04) 
0·70 
(0·43-1·14) 
1·26 
(0·86-1·84) 
0·35 
(0·18-0·69) 
Down’s syndrome 
(moderate to 
severe) 
1·38 
(0·64-2·96) 
2·25 
(1·14-4·46) 
0·69 
(0·27-1·76) 
2·69 
(1·39-5·21) 
- 
2·13 
(1·06-4·24) 
1·13 
(0·50-2·52) 
0·75 
(0·30-1·87) 
3·81 
(2·04-7·13) 
1·88 
(0·92-3·82) 
3·38 
(1·78-6·38) 
0·94 
(0·40-2·20) 
Angelman’s 
syndrome (severe 
to profound) 
0·65 
(0·35-1·18) 
1·06 
(0·64-1·74) 
0·32 
(0·14-0·73) 
1·26 
(0·79-2·02) 
0·47 
(0·24-0·94) 
- 
0·53 
(0·27-1·02) 
0·35 
(0·16-0·77) 
1·79 
(1·19-2·72) 
0·88 
(0·52-1·50) 
1·59 
(1·03-2·44) 
0·44 
(0·22-0·90) 
Neurofibromatosis 
type 1 (mild) 
1·22 
(0·59-2·55) 
2·00 
(1·04-3·83) 
0·61 
(0·24-1·53) 
2·39 
(1·28-4·47) 
0·89 
(0·40-1·99) 
1·89 
(0·98-3·65) 
- 0·67 
(0·27-1·62) 
3·39 
(1·88-6·10) 
1·67 
(0·85-3·28) 
3·00 
(1·65-5·47) 
0·83 
(0·37-1·90) 
Williams’ 
syndrome (mild) 
1·83 
(0·78-4·29) 
3·00 
(1·38-6·54) 
0·92 
(0·33-2·53) 
3·58 
(1·68-7·66) 
1·33 
(0·53-3·33) 
2·83 
(1·29-6·22) 
1·50 
(0·62-3·65) 
- 
5·08 
(2·45-10·53) 
2·50 
(1·12-5·58) 
4·50 
(2·15-9·41) 
1·25 
(0·49-3·17) 
Rett’s syndrome 
(severe to 
profound) 
0·36 
(0·21-0·61) 
0·59 
(0·40-0·88) 
0·18 
(0·08-0·39) 
0·70 
(0·49-1·01) 
0·26 
(0·14-0·49) 
0·56 
(0·37-0·84) 
0·30 
(0·16-0·53) 
0·20 
(0·09-0·41) 
- 
0·49 
(0·32-0·77) 
0·89 
(0·65-1·21) 
0·25 
(0·13-0·47) 
CHARGE (normal 
to severe) 
0·73 
(0·39-1·37) 
1·20 
(0·71-2·02) 
0·37 
(0·16-0·84) 
1·43 
(0·88-2·35) 
0·53 
(0·26-1·09) 
1·13 
(0·66-1·93) 
0·60 
(0·30-1·18) 
0·40 
(0·18-0·89) 
2·03 
(1·30-3·17) 
- 
1·80 
(1·14-2·85) 
0·50 
(0·24-1·04) 
Cohen’s syndrome 
(mild to severe) 
0·41 
(0·24-0·70) 
0·67 
(0·44-1·01) 
0·20 
(0·09-0·44) 
0·80 
(0·54-1·17) 
0·30 
(0·16-0·56) 
0·63 
(0.41-0.97) 
0·33 
(0·18-0·61) 
0·22 
(0·11-0·46) 
1·13 
(0·82-1·55) 
0·56 
(0·35-0·88) 
- 0·28 
(0·14-0·54) 
Noonan’s 
syndrome 
(normal–
moderate) 
1·47 
(0·67-3·21) 
2·40 
(1·19-4·85) 
0·73 
(0·28-1·91) 
2·87 
(1·45-5·67) 
1·07 
(0·45-2·50) 
2·27 
(1·11-4·62) 
1·20 
(0·53-2·74) 0·80 
(0·32-2·03) 
4·07 
(2·13-7·77) 
2·00 
(0·96-4·15) 
3·60 
(1·86-6·96) 
- 
The associated degree of intellectual disability for each syndrome is shown in parentheses in the first column. ASD=autism spectrum disorder.  
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Figure 3: Likelihood of ASD phenomenology in each syndrome compared with the general population 
 
OR=odds ratios. ASD=autism spectrum disorder 
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